secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001193125-26-123543
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer
--------------------------------------------------------------------------------

- Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
- Approval based on ROSELLA trial: 35% reduction in risk of death (HR 0.65, median OS 16.0 vs 11.9 months).
- Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).
- Most common adverse reactions: decreased hemoglobin, neutrophils, fatigue, nausea, diarrhea, rash, decreased appetite.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/0001193125-26-123543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-123543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer